---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Acetylcholinesterase inhibitors"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Acetylcholinesterase inhibitors. Topics: Pyridostigmine as initial symptomatic treatment: international consensus guidance; Pyridostigmine dosing, adverse effects, and second-line symptomatic agents: Nordic guidance; FDA-labeled indication and dosing: pyridostigmine. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/acetylcholinesterase-inhibitors"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Acetylcholinesterase inhibitors

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Acetylcholinesterase Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

### Pyridostigmine as initial symptomatic treatment: international consensus guidance

> “Pyridostigmine should be part of the initial treatment in most patients with MG. Pyridostigmine dose should be adjusted as needed based on symptoms. The ability to discontinue pyridostigmine can be an indicator that the patient has met treatment goals and may guide the tapering of other therapies.”
> “Corticosteroids or IS therapy should be used in all patients with MG who have not met treatment goals after an adequate trial of pyridostigmine.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.1.1-2"></a>

### Pyridostigmine dosing, adverse effects, and second-line symptomatic agents: Nordic guidance

> “Pyridostigmine represents the first‐line symptomatic treatment, while ambenonium and beta adrenergic agonists are second‐line options.”
> “Pyridostigmine dosage is titrated individually, where 30–60 mg every 4–6 h is a typical adult dose”
> “In a Dutch–Belgian cohort, 91% reported side effects from pyridostigmine, and one in four discontinued the treatment mainly due to side effects”
> “Pyridostigmine in optimal dose should be given as a first‐line symptomatic treatment in most patients with MG. The optimal dose can vary according to activity needs and be adjusted by the patient accordingly. Terbutaline and salbutamol can be used as adjuvant symptomatic treatments.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.1-3"></a>

### FDA-labeled indication and dosing: pyridostigmine

> “MESTINON is useful in the treatment of myasthenia gravis.”
> “The size and frequency of the dosage must be adjusted to the needs of the individual patient.”
> “The average dose is ten 60 mg tablets or ten 5 mL teaspoonfuls daily, spaced to provide maximum relief when maximum strength is needed.”

Source: [Mestinon prescribing information (2023)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a851795e-b7a8-40c3-9922-5e79d3eb4d92)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
